Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joy of Love recall

This article was originally published in The Tan Sheet

Executive Summary

Jen-on Herbal Science International announces April 17 a voluntary nationwide recall of Joy of Love supplement product sold in 12-capsule blister packs packaged in a retail box. The City of Industry, Calif.-based firm recalled the product, marketed as a dietary supplement, after FDA investigators found the product is made with an ingredient close in structure to erectile dysfunction drug, vardenafil (Schering and GlaxoSmithKline's Levitra). Vardenafil may present an additional risk if used in combination with medications such as nitrates, which are found in certain Rx drugs used to treat conditions such as high blood pressure or heart disease. FDA ramped up surveillance of supplements marketed to treat erectile dysfunction in 2006 when a survey of 17 products revealed seven of the products as illegal drugs due to adulteration with active ingredients used in Rx ED treatments (1"The Tan Sheet" July 17, 2006, p. 4)...

You may also be interested in...



FDA Survey Of ED Supplements Shows Contamination With Viagra, Levitra

A "first-of-its-kind" FDA survey of 17 dietary supplements marketed to treat erectile dysfunction revealed that seven of the products are actually illegal drugs due to adulteration with active ingredients used in Rx ED treatments, the agency states in a July 12 release

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

Topics

UsernamePublicRestriction

Register

PS100455

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel